MedTrace Logo

Avastin and Taxotere for Esophagogastric Cancer

NCT00137813 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2018-11-01

No results posted yet for this study

Summary

The purpose of this study is to determine what effects (good and bad) bevacizumab (Avastin) and docetaxel (Taxotere), used in combination, have on metastatic gastric and esophageal cancer.

Conditions

Interventions

DRUG

Docetaxel

Given intravenously once a week for 3 out of four weeks for a minimum of 8 weeks and maximum of a year and a half

DRUG

Bevacizumab

Given intravenously once a week for every other week for a minimum of 8 weeks and a maximum of a year and a half

Sponsors & Collaborators

Principal Investigators

  • Peter Enzinger, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2006-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00137813 on ClinicalTrials.gov